Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis by Astier, Anne L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alterations in CD46-mediated Tr1 regulatory T cells in patients
with multiple sclerosis
Citation for published version:
Astier, AL, Meiffren, G, Freeman, S & Hafler, DA 2006, 'Alterations in CD46-mediated Tr1 regulatory T cells
in patients with multiple sclerosis' Journal of Clinical Investigation, vol. 116, no. 12, pp. 3252-7. DOI:
10.1172/JCI29251
Digital Object Identifier (DOI):
10.1172/JCI29251
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Clinical Investigation
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Research article
3252	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 116	 	 	 Number 12	 	 	 December 2006
Alterations in CD46-mediated Tr1 regulatory  
T cells in patients with multiple sclerosis
Anne L. Astier,1 Gregory Meiffren,2 Samuel Freeman,1 and David A. Hafler1
1Laboratory of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School,  
Boston, Massachusetts, USA. 2INSERM U503, Laboratory of Fundamental and Clinical Immunobiology, Lyon, France.
Loss	of	Treg	function	appears	to	be	a	critical	factor	in	the	pathogenesis	of	human	autoimmune	diseases.	
Attention	has	focused	on	defects	of	CD4+CD25high	Tregs,	and	techniques	have	been	developed	to	determine	
their	function.	In	contrast,	the	role	of	Tr1	regulatory	T	cells,	which	secrete	the	antiinflammatory	cytokine	
IL-10,	in	autoimmune	disease	has	not	been	well	assessed.	CD46	is	a	newly	defined	costimulatory	molecule	
for	T	cell	activation,	and	CD46-costimulated	human	T	cells	induce	a	Tr1	Treg	phenotype	with	considerable	
amounts	of	IL-10	secretion.	Here,	we	examined	the	role	of	Tr1	cells	in	patients	with	multiple	sclerosis	(MS)	by	
stimulating	CD4+	T	cells	with	anti-CD3	and	-CD46	mAbs	and	measuring	IL-10	secretion.	There	were	striking	
defects	in	the	induction	of	Tr1	cells	with	CD46	costimulation	as	measured	by	IL-10	but	not	IFN-γ	secretion	in	
patients	with	MS	compared	with	healthy	subjects.	This	loss	of	Tr1	cell–associated	IL-10	secretion	was	specific	
to	CD46	and	not	CD28	costimulation	and	was	associated	with	an	altered	regulation	of	the	CD46-Cy2	isoform	
that	differentially	regulates	T	cell	function	in	a	CD46-transgenic	murine	model.	These	data	demonstrate	a	
second	major	Treg	defect	in	human	autoimmune	disease	associated	with	the	CD46	pathway.
Introduction
MS is a complex genetic disease characterized by inflammation in 
the CNS white matter mediated by activated autoreactive lympho-
cytes (1–7). CD46, initially identified as a complement regulatory 
receptor for C3 and then as a receptor for several pathogens (8–10), 
was recently found to be a potent costimulatory molecule for 
human T cells (11, 12). This ubiquitously expressed determinant is 
a type I membrane protein, composed of 4 short consensus repeats 
and a region rich in serine, threonine, and proline followed by a 
transmembrane segment, an intracytoplasmic anchor of 12 amino 
acids, and a short cytoplasmic tail. Due to alternative splicing, 2 
distinct intracytoplasmic tails of 16 (Cyt1) or 23 (Cyt2) amino 
acids are generated (13) that differentially regulate T cell–induced 
inflammation in vivo (14). Importantly, CD46-costimulated 
human T cells in the presence of IL-2 acquire a Tr1-type Treg phe-
notype, secreting high amounts of IL-10 (15) and granzyme B (16). 
Depending on the costimulatory signals, CD46-activated T cells 
can also differentiate toward a Th1 response with increased IL-10, 
IL-2, and IFN-γ secretion but decreased IL-5 production (17).
Three major classes of immunoregulatory T cells have been 
described (18): Th2/Th3 cells (19, 20), CD4+CD25high cells (21, 22), 
and Tr1 cells (23). The immunoregulatory Tr1 cells were identi-
fied by Roncarolo and coworkers (24) and secrete IL-10, a potent 
immunosuppressive cytokine with pleiotropic activities on B, T, 
and mast cells. While previous experiments have suggested the 
importance of IL-10 in regulating EAE, a murine model of MS 
(25, 26), the role of Tr1 cells in patients with human autoim-
mune diseases such as MS has not been investigated ex vivo. 
The investigation of Tr1 cells is of particular interest in MS, as 
increases in T cell IFN-γ and IL-12 secretion (27) and increases 
in IL-12p40 mRNA with decreases in IL-10 mRNA	expression 
(28) have been observed.
Recently, a number of groups have demonstrated a defect in 
the CD4+CD25high Tregs in patients with MS (29–31) and other 
autoimmune diseases (5, 32, 33). Considering the central role of 
IL-10 and Tr1 cells in regulating immune responses, we postulated 
that human autoimmune disease would have multiple defects in 
immunoregulatory T cells and that defects in Tr1 cells would be 
observed. As CD46-activated T cells acquire a Tr1 phenotype, we 
determined whether CD46 activation was impaired in patients 
with MS. A striking difference was observed between healthy 
donors and patients, in that little to no IL-10 was secreted by 
CD46-activated T cells from patients with MS as compared with 
healthy donors. This defect was specific to CD46, as IL-10 secre-
tion upon CD28 stimulation was not affected. Furthermore, levels 
of IFN-γ secreted by CD46-activated T cells were not affected and 
reflected the proliferation of the cells. Moreover, while no differ-
ence in expression of CD46 cytoplasmic isoforms was detected in 
freshly isolated T cells, an increase in Cyt2 expression was observed 
in T cells from patients with MS upon CD46 activation, indicating 
that CD46 is dysregulated in patients with impaired IL-10 produc-
tion. These data demonstrate that human autoimmune diseases 
can be associated with multiple defects in Treg populations.
Results
Defect in IL-10 production by CD46-activated T cells in patients with MS. 
Taking advantage of the CD46 costimulatory pathway for induc-
tion of Tr1 cells (15), we directly analyzed Tr1 cells in patients with 
relapsing remitting MS as compared with healthy controls. Purified 
CD4+ T cells from patients with MS (Table 1) — either untreated 
(n = 13) or treated with IFN-β (n = 15) — as well as from healthy 
age-matched donors (controls, n = 18) were stimulated with anti-
CD3 and -CD28 or anti-CD3 and -CD46 mAbs in the presence of 
IL-2 to generate Tr1 cells. We and others have previously shown 
that T cell stimulation by C3b, a natural ligand for CD46, is similar 
to the activation induced by antibodies cross-linking this determi-
nant (14, 15). We used a suboptimal concentration of antibodies to 
better detect differences between MS and control groups (11). The 
Nonstandard	abbreviations	used: qRT-PCR, quantitative real-time PCR.
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degree of proliferation as determined by [3H]thymidine incorpora-
tion as well as IFN-γ and IL-10 secretion was measured (Figure 1). 
Decreased proliferation upon CD28 stimulation was observed in 
the treated group compared with healthy controls, while no sig-
nificant difference was detected in the untreated group (Figure 1A). 
This observation shows that the treatment affects the proliferative 
capacity of T cells, as previously reported (34, 35). Upon CD46 
stimulation, there were no statistically significant differences in 
proliferation observed in patients as compared with controls.
When cytokine secretion was quantified, a striking difference was 
observed between controls and patient groups (Figure 1A). Specifi-
cally, CD46-mediated IL-10 secretion decreased almost 4-fold and 
6-fold in treated and untreated patients with MS, respectively, com-
pared with control subjects (Figure 1A); no difference was observed 
between treated and untreated patients. With anti-CD28 costimula-
tion, a slight decrease in IL-10 production was observed in the treat-
ed group of patients, though this was associated 
with a decrease in proliferation. In contrast, the 
decrease in CD46-mediated IL-10 secretion was 
not due to an inability of CD4+ cells to enter into 
cell cycle, as the difference was observed with 
normalization of IL-10 secretion to proliferation 
(6-fold difference in the ratio of cell proliferation 
to IL-10 secretion for the treated group and 2-fold 
difference for the untreated group; Figure 1B). 
Therefore, the decrease in IL-10 was specific to 
CD46 costimulation. IFN-γ secretion was not 
significantly affected in MS patients, as decreases were similarly pro-
portional to proliferation (Figure 1B). The lack of IL-10 secretion 
was not due to decreases in T cell expression of CD46, which was 
similar in controls and patients with MS, as shown in Figure 2.
A defect in IL-10 secretion is also observed with stronger stimulation. 
We next determined whether the lack of IL-10 secretion could be 
overcome by stronger T cell receptor stimuli. A group of patients 
was stimulated with both suboptimal (2 μg/ml) and optimal con-
centrations of anti-CD3 mAbs (10 μg/ml; see ref. 11) (Figure 3A). 
When higher concentrations of antibodies were used to stimulate 
T cells, although a slight increase in IL-10 was observed for both 
healthy donors and patients with MS, the level of IL-10 secreted 
was again significantly lower for T cells from patients compared 
with those from healthy controls. Interestingly, while no difference 
in IFN-γ was detected at the lowest concentration of CD3 antibod-
ies, a significant difference was observed with a stronger stimula-
Figure 1
Decreases in IL-10 secretion were specific to CD46 and not CD28 costimulation. (A) Proliferation and cytokine production upon CD28 and CD46 
stimulation. CD4+ T cells from controls or either treated [MS (IFN-β)] or untreated (MS) patients with MS were stimulated with anti-CD3/CD28 
or anti-CD3/CD46 mAbs (2 μg/ml) in the presence of IL-2 (10 U/ml). After 3 days, supernatants were harvested; proliferation was assessed by 
[3H]thymidine incorporation; and IL-10 and IFN-γ concentrations were quantified by ELISA. There were significant decreases in CD28-costimu-
lated proliferation in the treated patients as compared with the control subjects (left; *P = 0.0137). There was a decrease in CD46-mediated IL-10 
secretion in treated (6-fold decrease; †P < 0.0001) and untreated (4-fold decrease; **P = 0.0038) patients with MS, compared with control sub-
jects (middle). There were modest decreases in IFN-γ secretion in patients with MS compared with control subjects (right panel; **P = 0.0098). 
Average IL-10 production (pg/ml): CD28 stimulation: controls = 2,599, MS (IFN-β) = 1,580, MS = 2,393; CD46 stimulation: controls = 1,261, MS 
(IFN-β) = 210, MS = 325. Average IFN-γ secretion (pg/ml): CD28 stimulation: controls = 7,786, MS (IFN-β) = 9,176 MS = 4,289; CD46 stimulation: 
controls = 4,996, MS (IFN-β) = 1,826, MS = 2,324. (B) The levels of cytokine secreted were normalized to the proliferation by calculating the ratio 
of proliferation to cytokine production. The decrease in CD46-mediated IL-10 secretion was not simply due to an inability of CD4+ cells to enter 
into cell cycle, as a significant difference was observed with normalization of IL-10 (left panel) but not IFN-γ (right panel) secretion to proliferation 
(almost 6-fold difference for the treated group [##P = 0.0026] and 2-fold difference for the untreated group [#P = 0.0403]).
Table 1
Age, sex, and EDSS scores of individuals in the study
	 Healthy	controls	 MS	patients	 IFN-β−treated	MS	patients
Age, yr (mean ± SD) 36.8 ± 7.6 48.7 ± 13.2 43.2 ± 12.0
Sex 9 F/9 M 9 F/4 M 11 F/4 M
EDSS score (mean ± SD) – 0.86 ± 0.75 2.26 ± 1.61
EDSS, expanded disability status scale.
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tion, albeit less pronounced than for IL-10 secretion (Figure 3A). 
Therefore, the lack of IL-10 secretion upon CD46 costimulation 
was observed at weak and strong strengths of signals through 
the T cell receptor. The decrease in IL-10 production was further 
confirmed at the RNA level by quantifying IL-10 by real-time PCR 
(data not shown). As IL-2 is of crucial importance in CD46-medi-
ated induction of Tr1, we examined whether the lack of IL-10 
secretion was corrected by increasing concentrations of exogenous 
IL-2. T cells isolated from healthy donors and patients were coact-
ivated by CD3/CD46 antibodies at either 2 μg/ml or 10 μg/ml, 
and proliferation as well as IL-10 secretion were assessed. As shown 
in Figure 3B, addition of higher concentrations of IL-2 did not 
significantly alter the ratio of proliferation to IL-10 production. 
Therefore, the lack of IL-10 secretion was not due to a lack of IL-2. 
Furthermore, the difference in IL-10 secretion between the control 
and the MS subjects was specific to the CD46 induction of Tr1 
cells and was not detected with CD28 costimulation.
Altered expression of CD46 cytoplasmic isoforms. To further inves-
tigate the mechanism for loss of IL-10 secretion with CD46 
costimulation in patients with MS, we examined the 2 cytoplas-
mic isoforms of CD46. As these 2 isoforms are coexpressed in any 
given tissue — except for brain and kidney, where a preferential 
expression of Cyt2 is observed (36) — their role in IL-10 secretion 
has not been elucidated in humans. In a CD46-transgenic murine 
model of T cell–dependent contact hypersensitivity reaction, 
these 2 intracellular tails exhibit opposite effects; Cyt1 inhibits 
the inflammatory reaction, whereas Cyt2 augments the inflam-
mation (14), and this is correlated with a decrease in secretion 
Figure 2
CD46 expression in healthy donors and patients with MS. CD46 expression at the cell surface of purified CD4+ T cells isolated from healthy 
donors (Controls), treated patients, or untreated patients was analyzed by flow cytometry using anti-CD46–FITC.
Figure 3
Defect in IL-10 production is independent of the strength of T cell 
stimulation. (A) A group of patients with MS was either stimulated 
with 2 μg/ml or 10 μg/ml of anti-CD3 and anti-CD46 antibodies, and 
cytokine production was determined by ELISA. Although increasing 
CD46 cross-linking augmented IL-10 production by T cells from both 
healthy controls and patients with MS, there was still a significant dif-
ference between these 2 groups, with lower IL-10 secretion in patients 
with MS. Average IL-10 production (pg/ml): controls = 1,539, MS = 508 
at 1 μg/ml; controls = 2,684, MS = 818 at 10 μg/ml. Average IFN-γ 
secretion: controls = 5,021, MS = 2,656 at 1 μg/ml; controls = 6,781, 
MS = 2,466 at 10 μg/ml. (B) T cells were stimulated at either 2 μg/ml 
or 10 μg/ml of anti-CD3 and anti-CD46 antibodies in the presence 
of increasing concentrations of IL-2, and proliferation as well as 
IL-10 secretion were measured. The levels of cytokine secreted were 
normalized to the proliferation by calculating the ratio of proliferation 
to IL-10 production.
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of IL-2 and IL-10, respectively, as well as distinct effects on CD4 
proliferation and CD8 cytotoxicity. Thus, the levels of expression 
of these intracytoplasmic isoforms might regulate the outcome of 
the response initiated by CD46 engagement. As we demonstrated 
that IL-10 secretion was impaired in patients with MS, we went on 
to examine the relative expression of Cyt1 and Cyt2 in T cells from 
controls and patients. We developed a quantitative real-time PCR 
(qRT-PCR) assay by designing couples of primers specific for each 
cytoplasmic isoform (C. Rabourdin-Combe, personal communi-
cation). The forward primer for Cyt1 was chosen in the Cyt1-spe-
cific exon (exon 13), while the Cyt2 forward primer was designed 
to overlap the junction between exons 12 and 14 (Figure 4A). The 
purity of the products amplified by PCR was then assessed by 
their dissociation curve (Figure 4B) and by analysis on gels (data 
not shown). Similar amplification efficacy (1.92) was calculated 
for each couple of primers (Table 2). The levels of expression of 
CD46 cytoplasmic isoforms in resting and CD46-activated T 
cells were then analyzed. No significant difference was observed 
between patients and healthy controls in freshly isolated T cells 
(Figure 5A). However, upon stimulation, significant increases in 
the expression of the CD46-Cyt2 isoform were detected in T cells 
from patients with MS, while no such differences were observed 
for the Cyt1 isoform (Figure 5B).
Discussion
We and others have reported a decrease in CD4+CD25high Treg 
function in patients with MS (29, 30, 37). In this report, we now 
show a second major Treg defect in human autoimmune disease 
associated with the CD46 pathway. Indeed, T cells isolated from 
patients with MS have impaired IL-10 production when activated 
by CD46, a costimulatory molecule associated with Tr1 cell dif-
ferentiation. This lack of IL-10 secretion was specific to CD46 
costimulation, as no significant decrease in IL-10 secretion was 
detected with CD28 activation. No difference in IL-10 produc-
tion was observed between treated and untreated patients. An 
increase in IL-10 production is associated with remissions (38, 39) 
and IFN-β treatment (40). However, we did not observe any 
increase in IL-10 secretion with IFN-β therapy. This suggests that 
IFN-β might not be acting on Tr1 cells but could act on Th2 cells 
or other types of cells that secrete IL-10.
The reduced secretion of IL-10 by Tr1 cells from patients with 
MS was associated with increased expression of the Cyt2 iso-
form of CD46, as assessed by qRT-PCR, albeit in a small number 
of patients. In a CD46-transgenic murine model, Cyt1 inhibits 
inflammation whereas Cyt2 augments inflammation (14). We did 
not observe an increase in expression of the Cyt1 isoform in either 
healthy donors or patients with MS, while a significant increase in 
Cyt2 expression was detected in patients. As this is the first report 
to the best of our knowledge of a modulation of CD46 isoforms in 
human cells, our data suggest that CD46-Cyt2 is the most impor-
tant isoform in the regulation of inflammation.
We did not measure the phenotypic characteristics of the dif-
ferent subpopulations of T cells in the patients. Thus, it will be 
of interest to determine whether the different subpopulations 
of CD8+, CD4+, CD45RA+, and CD45RO+ T cells in patients are 
linked to alterations in CD46 signaling.
In T cells, CD46 activation induces the activation of numerous 
proteins involved in cell signaling (11, 12, 17). Both cytoplas-
mic domains of CD46 contain signaling motifs and can associ-
ate with kinases when transfected in murine macrophages (41). 
However, these 2 isoforms have distinct characteristics. The Cyt1 
isoform associates with the signaling scaffold protein discs, large 
homolog 4 (Dlg4), which is important for neuronal signaling and 
required for the polarized expression of CD46 in epithelial cells 
(42). Expression of human CD46-Cyt1 in mouse macrophages 
enhances the production of nitric oxide in response to measles 
virus infection (43). The Cyt2 isoform can be phosphorylated on 
tyrosine by Lck in Jurkat cells and c-Yes in epithelial cells (44, 45). 
We observed an altered pattern of expression of these isoforms 
in patients with MS, and together with the results of these pre-
vious reports, this argues in favor of the notion that different 
active transduction pathways are mediated by the 2 cytoplasmic 
isoforms of CD46 in human T cells.
It is thought that many allelic variants lead to a high risk of 
developing the complex genetic disease MS (4). Similarly, it is 
thought that there is a multitude of different immunologic 
Table 2
Sequences, amplification efficacy, amplicon size, and melting temperature for each set of primers
Isoform	 Forward	sequence	 Reverse	sequence	 Amplification	efficacy	 Tm	 Amplicon	size
Cyt1 CTAACTGATGAGACCCACAGAGAAGT TCAGCTCCACCATCTGCTTTC 1.997 75.7°C 109 bp
Cyt2 GAAGAAAGGGAAAGCAGATGGT CCTCTCTGCTCTGCTGGAGTG 1.9203 78.9°C 80 bp
Tm, melting temperature.
Figure 4
qRT-PCR for the detection of CD46 cytoplasmic isoforms. (A) Design 
of the primers used for the qRT-PCR assay (using SYBR Green) allow-
ing the specific detection of each isoform. (B) Dissociation curve for 
each amplified dimer. Cm, common exon to both cytoplasmic isoforms; 
TM, transmembrane domain.
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alterations that ultimately lead to the profound loss of toler-
ance associated with CNS white matter inflammation. Future 
investigations can examine these defects in Tr1 cells associated 
with decreases in IL-10 secretion by conducting whole-genome 
association scans to determine whether these cytokine defects are 
related to primary genetic or environmental influences on disease 
pathogenesis. Nevertheless, our results suggest that pharmaco-
logic interventions that induce IL-10 secretion by CD4+ cells are 
viable approaches in patients with MS.
T cell activation through the CD46 pathway was also found 
to be altered in patients with uremia undergoing hemodialy-
sis with increased T cell IL-10 production (46). In this clinical 
situation, no correlation with CD46 isoforms was identified 
by semiquantitative RT-PCR analysis. Furthermore, in uremia, 
increases in IL-10 secretion correlated with increases in pro-
liferation and thus might simply reflect a hyperproliferative 
state unrelated to increases in numbers of Tr1 cells. This is also 
consistent with the lack of change in CD46 isoform expression 
observed in these uremic patients.
Defects in CD4+CD25high Tregs have been observed in different 
autoimmune diseases including MS, type 1 diabetes, and rheu-
matoid arthritis (32, 33, 47). Our results are consistent with the 
hypothesis that there are multiple immunologic “hits” required 
to allow autoimmune diseases to occur. It will be of interest to 
examine other human autoimmune diseases to determine whether 
defects in CD46-mediated Tr1 cells are specific to MS or, as expect-
ed, are part of the common autoimmune disease phenotype. Ulti-
mately, understanding the precise signaling pathways associated 
with IL-10 secretion may allow the development of new therapeu-
tic approaches for the treatment of autoimmune diseases.
Methods
Subjects. Peripheral blood was obtained after receipt of informed con-
sent from healthy subjects (n = 18; mean age: 37.3 ± 7.6) and MS patients 
(n = 28; mean age: 45.9 ± 13; mean expanded disability status scale [EDSS] 
score: 1.56 ± 1.18). All patients were seen at the Partners Multiple Sclero-
sis Center at Brigham and Women’s Hospital. MS patients consisted of 
a group of untreated relapsing-remitting MS patients (n = 13) that had 
not received steroids in the last 3 months prior to blood drawing, nor 
IFN-β in the 10 months prior to blood drawing, nor immunosuppres-
sive therapy in the 3 years prior to blood drawing, as well as a group of 
IFN-β–treated patients (n = 15). None of the patients were treated with 
glatiramer acetate prior to blood drawing.
Cell stimulation. PBMCs were isolated from heparinized venous blood 
by Ficoll-Hypaque density gradient centrifugation (Pharmacia LKB Bio-
technology). CD4+ T cells were then negatively isolated using magnetic 
beads (CD4 isolation kit II; Miltenyi Biotec; >90% purity). T cells were then 
cultured in 96-well plates precoated with anti-CD3 (OKT3; 2–10 μg/ml), 
anti-CD28 (2D10; 2 μg/ml), or anti-CD46 (2–10 μg/ml) (20.6; kindly 
provided by C. Rabourdin-Combe, INSERM U503, Lyon, France) in the 
presence of rhIL-2 (10–100 U/ml) for 3 days for proliferation and ELISA 
experiments. For qRT-PCR analysis, cells were stimulated in 6-well plates 
precoated with anti-CD3 and -CD46 antibodies at similar concentrations. 
Cell-surface expression of CD46 was assessed by flow cytometry using 
anti-CD46–FITC (BD Biosciences).
Proliferation assay and ELISA. Proliferation was determined by incorpora-
tion of [3H]thymidine. Cytokine production was determined using ELISA 
specific for human IL-10 (BD Biosciences — Pharmingen) and IFN-γ (Endo-
gen; Pierce Biotechnology).
qRT-PCR for the detection of CD46 cytoplasmic isoforms. RNAs were extracted 
using TRIzol (Invitrogen) following the instructions of the manufacturer. 
cDNA were then prepared using the Advantage RT-PCR kit (Clontech; 
Cambrex). CD46 cytoplasmic isoforms were amplified by SYBR Green 
qRT-PCR (ABI) using primers specific for each cytoplasmic isoform, as 
described in Results, with the following sequences: Cyt1 forward, CTA-
ACTGATGAGACCCACAGAGAAGT; Cyt1 reverse, TCAGCTCCAC-
CATCTGCTTTC; Cyt2 forward, GAAGAAAGGGAAAGCAGATGGT; 
Cyt2 reverse, CCTCTCTGCTCTGCTGGAGTG. The difference in Ct was 
normalized to the housekeeping gene S9 [ΔCt = Ct(Cyt) – Ct(S9)], using 
the following primers: S9 forward, CCGCGTGAAGAGGAAGAATG; S9 
reverse; TTGGCAGGAAAACGAGACAAT. Primer sequences were deter-
mined using Primer Express software (Applied Biosystems) as well as 
Beacon Designer (Premier Biosoft International). The specificities of the 
primers were checked by BLAST (http://www.ncbi.nlm.nih.gov/blast/) and 
PCR simulation using Amplify (freeware from Bill Engels; http://engels.
genetics.wisc.edu/amplify/). The relative expressions of each isoform were 
then normalized to their expression at time 0, according to the following 
equation: mRNA expression = 2–(ΔCt (time X) – ΔCt (t0). After PCR amplification, 
a ramping was performed to check the purity of the products amplified 
(see Figure 2A). To quantify the amplification efficacy of the primers, 
cDNA from HeLa and 293T cells was amplified by PCR. PCR products 
were then diluted with a log dilution factor and reamplified by SYBR 
Figure 5
Aberrant CD46 cytoplasmic isoform expression in T cells from MS 
patients. (A) Relative expression of each isoform in freshly isolated T 
cells from healthy controls and either treated or untreated patients with 
MS. CD46 isoform expression was analyzed in T cells isolated from 
healthy control or MS patients. The ΔCt value is plotted [ΔCt = Ct (Cyt) 
– Ct (S9)]. (B) Relative increase in expression of CD46 cytoplasmic 
isoforms after CD46 stimulation. Cyt1 and Cyt2 expression in activated 
T cells was determined after stimulation by CD3/CD46 after 3 or 24 
hours. Their expression relative to expression at t0 is represented and 
expressed in AU.
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Green qRT-PCR. The efficacy of amplification (E) was determined accord-
ing to the following equation: E = 10(–1/slope), using the slope of the regres-
sion curve obtained by plotting Ct values as a function of dilutions.
Statistics. The groups were analyzed using Prism software (version 4.0a; 
GraphPad Software Inc.) and compared using the Mann-Whitney U test, 
a nonparametric test that does not assume Gaussian variation. ELISA, 
proliferation, and qRT-PCR data represent the average of triplicate wells. 
P values less than 0.05 were considered significant.
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